Evidence map›Paper›PMID 42749679›Full record

ArticlemAbs2026

Predicting non-specific binding of VHHs using machine learning models with cluster-aware validation.

Valentin Stanev, Federico Devalle, Mehdi Boroumand, Maryam Pouryahya, Isabelle Sermadiras, Jenna Caldwell, Kuan-Lin Chen, Jay Hyun Jo, Rohan Jain, Bismark Amofah and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in mAbs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Valentin StanevBiopharmaceutical Development, R&D, AstraZeneca, Gaithersburg, MD, USA.ORCID 0000-0001-6129-133X
Federico DevalleBiopharmaceutical Development, R&D, AstraZeneca, Gaithersburg, MD, USA.
Mehdi BoroumandBiopharmaceutical Development, R&D, AstraZeneca, Gaithersburg, MD, USA.
Maryam PouryahyaBiopharmaceutical Development, R&D, AstraZeneca, Gaithersburg, MD, USA.
Isabelle SermadirasBiologics Engineering, R&D, AstraZeneca, Gaithersburg, MD, USA.
Jenna CaldwellBiopharmaceutical Development, R&D, AstraZeneca, Gaithersburg, MD, USA.
Kuan-Lin ChenBiologics Engineering, R&D, AstraZeneca, Gaithersburg, MD, USA.ORCID 0000-0001-5838-7074
Jay Hyun JoBiologics Engineering, R&D, AstraZeneca, Gaithersburg, MD, USA.
Rohan JainBiopharmaceutical Development, R&D, AstraZeneca, Gaithersburg, MD, USA.
Bismark AmofahBiologics Engineering, R&D, AstraZeneca, Gaithersburg, MD, USA.
Tony PhamBiologics Engineering, R&D, AstraZeneca, Gaithersburg, MD, USA.
Mark HutchinsonBiologics Engineering, R&D, AstraZeneca, Gaithersburg, MD, USA.
Sharfa FarzandhBiologics Engineering, R&D, AstraZeneca, Gaithersburg, MD, USA.
Jen DiChiaraBiologics Engineering, R&D, AstraZeneca, Gaithersburg, MD, USA.
Chacko ChakiathBiologics Engineering, R&D, AstraZeneca, Gaithersburg, MD, USA.
Tom DietheCentre for Artificial Intelligence, R&D, AstraZeneca, Cambridge, UK.
Andrew DippelBiologics Engineering, R&D, AstraZeneca, Gaithersburg, MD, USA.ORCID 0000-0003-3453-0803
Gilad KaplanBiologics Engineering, R&D, AstraZeneca, Gaithersburg, MD, USA.ORCID 0000-0003-1374-305X
Rebecca Croasdale-WoodBiologics Engineering, R&D, AstraZeneca, Gaithersburg, MD, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Propensity for nonspecific binding-also known as polyreactivity-is a serious developability risk factor for biotherapeutic candidates. To minimize this risk, drug companies are increasingly relying on

Indexed as

Immunoglobulin Heavy ChainsMachine LearningSingle-Domain AntibodiesAnimalsHumansPrediction AlgorithmsPredictive Learning ModelsProtein BindingImmunoglobulin Heavy ChainsSingle-Domain Antibodiesin silicoMachine learningnanobodiesnonspecific bindingpolyreactivityVHH

Identifiers

PMID42749679
PMCPMC13596884

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.